Use of low-dose peginterferon alpha-2a (40kD) 628 (pegasys (R)) to treat hepatitis C-infected end-stage renal disease patients undergoing haemodialysis: Interim results from a randomised study


Peck-Radosavljevic M., Boletis J., Besisik F. , Ferraz M. L. , Alric L., Samuel D., ...More

42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Barcelona, Spain, 11 - 15 April 2007, vol.46 identifier